Profile
RGC ZTS TAK HLN TEVA VTRS
Company Name Regencell Bioscience Holdings Limited Zoetis Inc. Takeda Pharmaceutical Company Limited Haleon plc Teva Pharmaceutical Industries Limited Viatris Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic
Market Cap $13.46B $56.15B $54.43B $49.48B $39.78B $14.94B
Employees 0.01K 13.80K 49.28K 24.56K 37.00K 32.00K
CEO Yat-Gai Au Kristin C. Peck Christophe Weber Brian James McNamara Richard D. Francis Scott Andrew Smith
Ratings
RGC ZTS TAK HLN TEVA VTRS
Quant Rating Score 2 3 3 4 3 2
Quant Rating Sell Neutral Neutral Buy Neutral Sell
Trading
RGC ZTS TAK HLN TEVA VTRS
Last Close $12.93 $118.8 $14.14 $9.68 $24.59 $10.66
High 52 $877 $178.71 $15.52 $11.41 $25.83 $13.37
Low 52 $3.58 $118.8 $12.89 $8.73 $12.82 $7.26
Price vs. 52 Week High -98.53 % -33.52 % -8.89 % -15.16 % -4.8 % -20.27 %
Price vs. 52 Week Low 261.17 % 0 % 9.7 % 10.88 % 91.81 % 46.83 %
Total Return
RGC ZTS TAK HLN TEVA VTRS
1 Month Return -25.73 % -17.53 % 0.71 % 2.11 % 27.34 % 4.82 %
3 Month Return -2.96 % -21.96 % -6.73 % -0.05 % 36.16 % 0.28 %
6 Month Return -96.71 % -27.13 % 0.21 % -10.37 % 45.16 % 20.59 %
9 Month Return 249.46 % -24.08 % 1.73 % -3.1 % 48.4 % -1.84 %
YTD Return 161.74 % -27.09 % 6.8 % 1.47 % 11.57 % -14.38 %
1 Year Return 99.54 % -32.33 % 3.82 % 2.11 % 46.28 % -18.31 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
RGC ZTS TAK HLN TEVA VTRS
Dividend Yield Percentage (TTM) - 1.59 % 3.78 % 1.41 % - 3.7 %
Dividend Paid and Capex Coverage Ration (TTM) - 1.89 % 2.23 % 2.01 % 4 % 2.09 %
Dividend Per Share (TTM) - 2.03 % 198 % 0.06 % - 0.48 %
Payout Ratio (TTM) - 32.55 % 277.04 % 27.27 % - -15.34 %
Growth
RGC ZTS TAK HLN TEVA VTRS
Asset Growth -31.79 % -0.34 % 0.76 % 3.61 % -12.97 %
Gross Profit Growth 47.32 % 9.63 % -0.19 % 10.86 % -12.66 %
Revenue Growth - 8.33 % -0.61 % 4.32 % -4.46 %
Revenue 3 Year - 24.31 % 19.01 % 11.71 % -16.52 %
Revenue 5 Year - 55.65 % 33.95 % -1.27 % -39.86 %
Revenue 10 Year - 113.39 % 33.95 % -34.65 % -36.45 %
EBIT Growth 17.85 % 5.67 % 13.52 % -9.52 % -109.43 %
Net Income Growth 16.68 % 6.06 % 37.46 % 185.97 % -1259.41 %
Net Income 3 Yeari Growth Per Share 51.71 % 27.46 % 4.91 % 155.65 % 49.38 %
Net Income 5 Yeari Growth Per Share -328.63 % 74.46 % 122.63 % 133.65 % -1871.56 %
Net Income 10 Yeari Growth Per Share -790.58 % 370.4 % 122.63 % -33.98 % -122.71 %
Operating Income Growth 20.41 % 10.52 % 10.52 % 1131.35 % -98.68 %
Operating Cash Flow Growth (CFG) 22.19 % 25.5 % 9.57 % -35.33 % -17.74 %
Operating 3 Year CFG 40.89 % 39.36 % 71.6 % 0.19 % -22.68 %
Operating 5 Year CFG -316.32 % 73.18 % 196.04 % 29.24 % -40.08 %
Operating 10 Year CFG -673.64 % 420.39 % 196.04 % -77.86 % -24.47 %
EPS Growth 17.24 % 7.68 % 33.33 % 184.83 % -1262.28 %
EPS Diluted Growth 17.24 % 7.89 % 33.33 % 182.76 % -1269.98 %
Book Value Per Share -40.86 % -2.96 % -1.63 % 36.19 % -8.42 %
Share Holder 3 Year Equity Growth Per Share -71.52 % 9.65 % -37.97 % -2.08 % -7.88 %
Share Holder 5 Year Equity Growth Per Share 278.12 % 85.42 % -40.16 % -24.81 % -26.41 %
Share Holder 10 Year Equity Growth Per Share 356.83 % 301.38 % -40.16 % -80.23 % 90.51 %
Dividend Per Share Growth - 15.33 % 49.01 % - 0.45 %
Dividend 3 Year Growth Per Share - 73.18 % -49.79 % - 45.93 %
Dividend 5 Year Growth Per Share - 163.51 % -49.97 % - -
Dividend 10 Year Growth Per Share - 493.89 % -49.97 % -100 % -
Debt Growth 534.95 % -0.16 % 6.83 % -3.86 % -22.13 %
Free Cash Flow Growth 18.49 % 41.76 % 16.27 % -43.99 % -14.98 %
Updated On 30 Jun 2025 31 Dec 2024 31 Dec 2024 31 Dec 2025 31 Dec 2024
Profitability
RGC ZTS TAK HLN TEVA VTRS
Gross Profit Margin TTM - 70.63 % 56.31 % 61.81 % 51.76 % 36.07 %
Return on Assets TTM -62.27 % 17.49 % 0.73 % 4.78 % 3.48 % -9.73 %
Return on Equity TTM -61.93 % 53.56 % 1.58 % 9.4 % 20.09 % -22.69 %
Return on Capital Employed TTM -74.04 % 26.48 % 3.76 % 8.34 % 11.54 % -8.43 %
Net Income Per EBT TTM 100 % 79.59 % 54.99 % 76.52 % 114.62 % 95.92 %
EBT Per Ebit TTM 95.07 % 94.2 % 42.72 % 88.09 % 39.3 % 149.32 %
EBIT Per Revenue TTM - 37.63 % 10.77 % 20.49 % 18.15 % -18.25 %
Cash Flow To Debt Ratio TTM - 40.09 % 23.13 % 12.02 % 11.62 % 13.47 %
Receivables Turnover TTM - 6.1 5.89 5.14 4.68 3.94
Payables Turnover TTM - 6.73 4.17 1.18 3.31 6.81
Inventory Turnover TTM - 1.12 1.39 3.72 2.63 2.2
Fixed Asset Turnover TTM - 241.44 % 214.23 % 589.57 % 392.13 % 488.38 %
Asset Turnover TTM - 61.99 % 28.97 % 34.62 % 42.58 % 37.25 %
Operating Cash Flow Per Share TTM - 6.58 710.55 0.11 1.76 1.7
Free Cash Flow Per Share TTM - 5.06 589.53 0.1 1.32 1.37
Cash Per Share TTM 0.99 % 470.54 % 48236.45 % 7.46 % 309.55 % 99.36 %
Operating Cash Flow Sales Ratio TTM - 31.03 % 25.14 % 9.32 % 11.64 % 14.04 %
Free Cash Flow Operating Cash Flow Ratio TTM - 76.82 % 82.97 % 90.65 % 74.99 % 80.65 %
Cash Flow Coverage Ratios TTM - 40.09 % 23.13 % 12.02 % 11.62 % 13.47 %
Price To Free Cash Flows Ratio TTM - 25.07 8.89 38.08 26.3 9.34
Price To Operating Cash Flows Ratio TTM - 19.35 7.38 35.1 19.76 7.62
Price Cash Flow Ratio TTM - 19.35 7.38 35.1 19.76 7.62
Income Statement (TTM)
RGC ZTS TAK HLN TEVA VTRS
Revenue $0B $9.26B $4581.55B $11.23B $17.26B $14.74B
Gross Profit $-0B $6.4B $3001.33B $6.95B $8.94B $5.62B
Gross Profit Ratio 0% 69.1% 65.51% 61.85% 51.79% 38.15%
EBITDA $-0B $3.87B $1210.51B $2.51B $3.14B $2.82B
Net Income $-0B $2.49B $107.93B $1.44B $1.41B $-0.63B
EPS Diluted -0.01 5.47 33.62 0.32 1.2 -0.53
Balance Sheet (MRQ)
RGC ZTS TAK HLN TEVA VTRS
Long Term Debt $0B $5.39B $3966.33B $8.62B $15.56B $14.22B
Total Liabilities $0B $9.47B $7312.37B $18.09B $32.83B $22.87B
Total Equity $0B $4.77B $6935.98B $16.22B $7.91B $18.64B
Total Investments $0B $0.03B $382.4B $0.14B $0B $1.7B
Total Debt $0B $6.74B $4515.27B $10.1B $17.38B $14.31B
Total Assets $0.01B $14.24B $14248.34B $34.32B $40.75B $41.5B
Cash Flow Statement (TTM)
RGC ZTS TAK HLN TEVA VTRS
Net Income $-0B $2.5B $107.93B $1.44B $1.42B $-0.63B
Inventory $0B $-0.04B $-34.97B $0.22B $0.15B $-0.72B
Dividends Paid $0B $-0.79B $-302.5B $-0.57B $0B $-0.57B
Operating Cash Flow $-0B $2.95B $1057.18B $2.3B $1.65B $2.3B
Capital Expenditure $-0B $-0.66B $-200.8B $-0.25B $-0.5B $-0.33B
Related Stocks
Ticker Name Price
ACB Aurora Cannabis Inc. 3.48
ACOR Acorda Therapeutics, Inc. 0.661
ACRX AcelRx Pharmaceuticals, Inc. 0.86
ADMP Adamis Pharmaceuticals Corporation 0.775
ADMS Adamas Pharmaceuticals, Inc. 8.22
AERI Aerie Pharmaceuticals, Inc. 15.25
AGRX Agile Therapeutics, Inc. 1.51
AKAN Akanda Corp. 0.96
ALIM Alimera Sciences, Inc. 5.54
ALVO Alvotech 5.12
ALVOW Alvotech 0.4511
AMPH Amphastar Pharmaceuticals, Inc. 29.26
AMRX Amneal Pharmaceuticals, Inc. 14.52
AMYT Amryt Pharma plc 14.7
ANIP ANI Pharmaceuticals, Inc. 81.84
APUS Apimeds Pharmaceuticals US, Inc 1.62
AQST Aquestive Therapeutics, Inc. 4.11
ASRT Assertio Holdings, Inc. 12.74
ATNX Athenex, Inc. 0.2031
AVDL Avadel Pharmaceuticals plc 21.69
ETFs With Exposure to RGC
Ticker ETF Name Weight Percentage Price
GXC SPDR S&P China ETF 0.019342 101.23
ONEQ Fidelity Nasdaq Composite Index ETF 0.02 90.54
GSID Goldman Sachs MarketBeta International Equity ETF 0 74.1483
Unlock